Jon Stoessl

Last updated

Alexander Jon Stoessl [1] is a Canadian neurologist and Parkinson's disease researcher. He is the director of the Pacific Parkinson's Research Centre and Parkinson's Foundation Centre of Excellence at the University of British Columbia (UBC). He is also the head of the division of neurology at this university. [2] He is currently the President of the World Parkinson Coalition.

Contents

Early life and education

Stoessl was born in London, England. [3] In 1960, when Stoessl was a child, he and his family moved from England to London, Ontario, after his father was offered a job in Canada. [4] He received his medical degree from the University of Western Ontario in 1979, after which he completed an internship at McGill University and a residency in neurology at the University of Western Ontario, where he studied alongside Alastair Buchan. [4] [5]

Career

In 1984, Stoessl joined the faculty of the University of British Columbia, where he worked on the positron emission tomography program with Donald Calne for two years. [5] He then worked at the Neuroscience Research Centre in the UK for two years in the late 1980s. [4] In 1996, he joined the faculty of UBC again, where he has remained ever since. [5]

Scientific work

In 2001, Stoessl published a paper in Science which found that the placebo effect in Parkinson's disease might be due to patients' anticipation of benefit, and that substantial dopamine is released in the brains of Parkinson's patients in response to placebo administration. [4] [6] Subsequent research by Stoessl has found that dopamine is released in the brain of Parkinson's patients when they are given a placebo, but only if they are told the probability of it being a real drug is 75 percent. [7] [8] He has said that "In Parkinson's, as in many other conditions, there is an important placebo response and that can be measured with clinical outcomes." [9]

Awards and honors

Stoessl holds a Canada Research Chair. [2] He was awarded the fourth annual Donald Calne Lectureship in 2006 by Parkinson Society Canada [3] and was named a Member of the Order of Canada in 2007. [4] [5]

Related Research Articles

<span class="mw-page-title-main">Placebo</span> Substance or treatment of no therapeutic value

A placebo can be roughly defined as a sham medical treatment. Common placebos include inert tablets, inert injections, sham surgery, and other procedures.

<span class="mw-page-title-main">Apathy</span> State of indifference, or the suppression of emotions

Apathy is a lack of feeling, emotion, interest, or concern about something. It is a state of indifference, or the suppression of emotions such as concern, excitement, motivation, or passion. An apathetic individual has an absence of interest in or concern about emotional, social, spiritual, philosophical, virtual, or physical life and the world. Apathy can also be defined as a person's lack of goal orientation. Apathy falls in the less extreme spectrum of diminished motivation, with abulia in the middle and akinetic mutism being more extreme than both apathy and abulia.

<span class="mw-page-title-main">Arvid Carlsson</span> Swedish neuroscientist (1923–2018)

Arvid Carlsson was a Swedish neuropharmacologist who is best known for his work with the neurotransmitter dopamine and its effects in Parkinson's disease. For his work on dopamine, Carlsson was awarded the Nobel Prize in Physiology or Medicine in 2000, together with Eric Kandel and Paul Greengard.

<span class="mw-page-title-main">Hypokinesia</span> Decreased movement due to basal ganglia dysfunction

Hypokinesia is one of the classifications of movement disorders, and refers to decreased bodily movement. Hypokinesia is characterized by a partial or complete loss of muscle movement due to a disruption in the basal ganglia. Hypokinesia is a symptom of Parkinson's disease shown as muscle rigidity and an inability to produce movement. It is also associated with mental health disorders and prolonged inactivity due to illness, amongst other diseases.

<span class="mw-page-title-main">Apomorphine</span> Chemical compound

Apomorphine, sold under the brand name Apokyn among others, is a type of aporphine having activity as a non-selective dopamine agonist which activates both D2-like and, to a much lesser extent, D1-like receptors. It also acts as an antagonist of 5-HT2 and α-adrenergic receptors with high affinity. The compound is historically a morphine decomposition product made by boiling morphine with concentrated acid, hence the -morphine suffix. Contrary to its name, apomorphine does not actually contain morphine or its skeleton, nor does it bind to opioid receptors. The apo- prefix relates to it being a morphine derivative ("[comes] from morphine").

Donald Brian Calne,, is a Canadian neurologist who is a leading Parkinson's disease researcher.

J. William Langston is the founder and chief scientific officer, movement disorder specialist, and chief executive officer of the Parkinson's Institute and Clinical Center in Sunnyvale, California, the founding member of the Scientific Advisory Board for the Michael J. Fox Foundation and the Co-Editor-in-Chief of the Journal of Parkinson's Disease. He is a graduate of the University of Missouri School of Medicine. Langston was formerly a faculty member at Stanford University and Chairman of Neurology at Santa Clara Valley Medical Center in San Jose, California. Langston has authored or co-authored some 360 peer-reviewed articles in the field of neurology, most of which are on Parkinson's disease and related disorders. Langston gained national and international recognition in 1982 for the discovery of the link between a "synthetic heroin" contaminant (MPTP) and parkinsonism.

<span class="mw-page-title-main">Pramipexole</span> Dopamine agonist medication

Pramipexole, sold under the brand Mirapex among others, is medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS). In Parkinson's disease it may be used alone or together with levodopa. It is taken by mouth. Pramipexole is a dopamine agonist of the non-ergoline class.

<span class="mw-page-title-main">Dopamine agonist</span> Compound that activates dopamine receptors

A dopamine agonist(DA) is a compound that activates dopamine receptors. There are two families of dopamine receptors, D1-like and D2-like. They are all G protein-coupled receptors. D1- and D5-receptors belong to the D1-like family and the D2-like family includes D2, D3 and D4 receptors. Dopamine agonists are primarily used in the treatment of Parkinson's disease, and to a lesser extent, in hyperprolactinemia and restless legs syndrome. They are also used off-label in the treatment of clinical depression. The use of dopamine agonists is associated with impulse control disorders and dopamine agonist withdrawal syndrome (DAWS).

In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief from the symptoms.

<span class="mw-page-title-main">Dihydroergocryptine</span> Chemical compound

Dihydroergocryptine (DHEC), sold under the brand names Almirid and Cripar among others, is a dopamine agonist of the ergoline group that is used as an antiparkinson agent in the treatment of Parkinson's disease. It is taken by mouth.

<span class="mw-page-title-main">DaT scan</span> Diagnostic method

DaT Scan commonly refers to a diagnostic method, based on SPECT imaging, to investigate if there is a loss of dopaminergic neurons in striatum. The term may also refer to a brand name of Ioflupane (123I) tracer used for the study. The scan principle is based on use of the radiopharmaceutical Ioflupane (123I) which binds to dopamine transporters (DaT). The signal from them is then detected by the use of single-photon emission computed tomography (SPECT) which uses special gamma-cameras to create a pictographic representation of the distribution of dopamine transporters in the brain.

<span class="mw-page-title-main">Droxidopa</span> Synthetic amino acid/norepinephrine prodrug

Droxidopa is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitter norepinephrine (noradrenaline). Unlike norepinephrine, droxidopa is capable of crossing the protective blood–brain barrier (BBB).

<span class="mw-page-title-main">Parkinson's disease</span> Long-term degenerative neurological disorder

Parkinson's disease (PD), or simply Parkinson's, is a long-term neurodegenerative disease of mainly the central nervous system that affects both the motor system and non-motor systems. The symptoms usually emerge slowly, and as the disease progresses, non-motor symptoms become more common. Usual symptoms are tremor, slowness of movement, rigidity, and difficulty with balance, collectively known as parkinsonism. Parkinson's disease dementia, falls and neuropsychiatric problems such as sleep abnormalities, psychosis, mood swings, or behavioral changes may arise in advanced stages.

<span class="mw-page-title-main">Altinicline</span> Chemical compound

Altinicline is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models, and progressed as far as Phase II clinical trials for Parkinson's disease, where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.

<span class="mw-page-title-main">Sarizotan</span> Chemical compound

Sarizotan (EMD-128,130) is a selective 5-HT1A receptor agonist and D2 receptor antagonist, which has antipsychotic effects, and has also shown efficacy in reducing dyskinesias resulting from long-term anti-Parkinsonian treatment with levodopa.

<span class="mw-page-title-main">Andrew Lees (neurologist)</span> UK neurologist (born 1947)

Andrew John Lees FRCP FRCP(G) FMedSci is Professor of Neurology at the National Hospital for Neurology and Neurosurgery, Queen Square, London and University College London. In 2011 he was named as the world's most highly cited Parkinson's disease researcher.

<span class="mw-page-title-main">Ivar Mendez</span> Canadian neurosurgeon and neuroscientist

Ivar Mendez is a neurosurgeon, neuroscientist and Professor of Surgery at the University of Saskatchewan. He is internationally known for his work in cell transplantation for Parkinson's disease and the use of remote presence robotics in neurosurgery and primary health care. In December 2022, Mendez was appointed an officer of the Order of Canada for his pioneering work in the use of remote telemedicine and robotics to revolutionize the delivery of health and patient care.

Dopamine therapy is the regulation of levels of the neurotransmitter dopamine through the use of either agonists, or antagonists; and has been used in the treatment of disorders characterized by a dopamine imbalance. Dopamine replacement therapy (DRT) is an effective treatment for patients with decreased levels of dopamine. Often dopamine antagonists, compounds that activate dopamine receptors in the absence of that receptor's physiological ligand, the neurotransmitter dopamine, are used in this therapy. DRT has been shown to reduce symptoms and increase lifespan for patients with Parkinson's disease. Dopamine regulation plays a critical role in human mental and physical health. The neurons that contain the neurotransmitter are clustered in the midbrain region in an area called the substantia nigra. In Parkinson's patients, the death of dopamine-transmitting neurons in this area leads to abnormal nerve-firing patterns that cause motor problems. Research in patients with schizophrenia indicates abnormalities in dopamine receptor structure and function.

<span class="mw-page-title-main">Masud Husain</span> British professor of neuroscience, editor of Brain

Masud Husain FMedSci is a clinical neurologist and neuroscientist working in the UK. He is Professor of Neurology & Cognitive Neuroscience at the Nuffield Department of Clinical Neurosciences and Departmental of Experimental Psychology, University of Oxford, a Professorial Fellow at New College, Oxford, and Editor-in-Chief of the journal Brain. He was born in East Pakistan.

References

  1. ↑ Stoessl, Alexander Jon; Bushnell, Mary Catherine; Schulzer, Michael; Mak, Edwin; Troiano, Andre R.; Nandhagopal, R. (2010). "Response to Heat Pain Stimulation in Idiopathic Parkinson's Disease". Pain Medicine. 11 (6): 834–840. doi:10.1111/j.1526-4637.2010.00866.x. ISSN   1526-2375. PMID   20624238. S2CID   205686167.
  2. 1 2 "A. Jon Stoessl". UBC website. Retrieved 23 April 2015.
  3. 1 2 "Dr. A. Jon Stoessl recognized with 2006 Donald Calne Lectureship". Parkinson Society Saskatchewan. Retrieved 23 April 2015.
  4. 1 2 3 4 5 Holmes, D (November 2011). "Jon Stoessl: besotted with the brain". The Lancet. Neurology. 10 (11): 955. doi:10.1016/s1474-4422(11)70236-8. PMID   22014432. S2CID   12671041.
  5. 1 2 3 4 "Jon Stoessl". TRIUMF. Retrieved 23 April 2015.
  6. ↑ de la Fuente-Fernández, R; Ruth, TJ; Sossi, V; Schulzer, M; Calne, DB; Stoessl, AJ (10 August 2001). "Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease". Science. 293 (5532): 1164–6. doi:10.1126/science.1060937. PMID   11498597. S2CID   1477066.
  7. ↑ Lidstone, SC; Schulzer, M; Dinelle, K; Mak, E; Sossi, V; Ruth, TJ; de la Fuente-Fernández, R; Phillips, AG; Stoessl, AJ (August 2010). "Effects of expectation on placebo-induced dopamine release in Parkinson disease". Archives of General Psychiatry. 67 (8): 857–65. doi:10.1001/archgenpsychiatry.2010.88. PMID   20679593. S2CID   17116688.
  8. ↑ Harding, Anne (4 August 2010). "Brain's reward system helps drive placebo effect". Reuters. Retrieved 23 April 2015.
  9. ↑ Bootle, Olly (17 February 2014). "The medicine in our minds". BBC News. Retrieved 23 April 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.